Loading
Alzheimer Disease / Disease Models, Animal / Alzheimer's Disease · Journal article
Experimental Neurology · May 27, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical study demonstrating that ergosterol administration in a streptozotocin-induced rat model of Alzheimer's disease improves cognition and reduces markers of oxidative stress and neuroinflammation. Molecular docking suggests potential TLR4 interaction (docking score −3.318), but the work remains in the animal model phase with no quantified effect sizes, confidence intervals, or human validation.
Preclinical in-vivo animal model study with in-silico molecular docking. Streptozotocin-induced Alzheimer's disease rat model; specific eligibility criteria and group assignments not detailed.. Intervention: Ergosterol at 25, 50, and 100 mg/kg body weight, alone and in combination with donepezil. Compared with: Standard drug donepezil; control group (presumed STZ-only) not explicitly described..
Ergosterol docking score to TLR4: −3.318; donepezil −3.934 MMGBSA ΔG bind scores: ergosterol −36.9, donepezil −39.19 Ergosterol improved memory and learning in Morris water maze, Novel Object Recognition Test, and Elevated Plus Maze Test
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This preclinical work suggests ergosterol warrants further investigation as a potential neuroprotective agent, but human clinical trials are required before therapeutic recommendations can be made. The absence of quantified cognitive endpoints and effect sizes limits interpretation of the magnitude of benefit.
Animal model study with in-silico support showing ergosterol reduces oxidative stress and neuroinflammation in STZ-induced rat AD; no human data, mechanistic insight only, and lacks quantified effect sizes with confidence intervals.
As stated by the source record.
Quoted from the source exactly as published.
This preclinical work suggests ergosterol warrants further investigation as a potential neuroprotective agent, but human clinical trials are required before therapeutic recommendations can be made. The absence of quantified cognitive endpoints and effect sizes limits interpretation of the magnitude of benefit.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Oxidative stress and neuroinflammatory processes constitute pivotal pathogenic mechanisms in the progression of Alzheimer's disease (AD), an age-associated neurodegenerative disorder, as well as in other neurodegenerative conditions. This study is the first to integrate in-silico TLR4-targeted molecular docking of ergosterol with comprehensive in-vivo validation, thereby providing mechanistic insight into its potential role as a neuroprotective agent. The present experimental work aimed to explore the effects of ergosterol (25, 50, and 100 mg/kg body weight) and its combination with the standard drug donepezil, as an antioxidant and anti-inflammatory agent, in a streptozotocin (STZ) induced AD rat model. In silico docking studies were first performed, in which ergosterol and donepezil were docked to the TLR4 receptor (PDB ID: 2Z62). The docking scores of ergosterol and donepezil were - 3.318 and - 3.934, respectively, with MMGBSA ΔG bind scores of -36.9 and - 39.19, ergosterol demonstrated neuroprotective potential with supportive computational evidence suggesting possible TLR4 interaction. RMSD values for both ergosterol-TLR4 and donepezil-TLR4 complexes indicated stable binding interactions. In the in-vivo STZ model, ergosterol administration significantly improved memory and learning impairments, as assessed by the Morris water maze, Novel Object Recognition Test, and Elevated Plus Maze Test. It also reversed changes in glutathione and malondialdehyde levels and showed protective effects in the hippocampus. Moreover, ergosterol ameliorated neuroinflammation by reducing glial cell activation. These findings provide experimental evidence that ergosterol prevents memory loss, learning impairments, oxidative stress, and neuroinflammation in ICV-STZ rats. In conclusion, ergosterol, either alone or in combination with donepezil, may constitute a promising therapeutic strategy against AD through its dual action on oxidative stress and neuroinflammation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.